3. Vaccine Variation
3.1 The Parties acknowledge that Novavax has initiated development of new constructs against the emerging variants of SARS–CoV–2. In the event that Novavax proposes to manufacture a modified or booster version of the Vaccine, or a different vaccine against Covid–19, in order to increase effectiveness against variants of SARS–CoV–2 (in each case referred to as a “Variant Vaccine”), Novavax shall [***] notify Gavi. [***].
3.2 At any time during the Term of this Agreement, Gavi may provide written notice and the Parties will thereafter conduct good faith discussions to execute an addendum to the Agreement related to substitution of doses of Vaccine for doses of Variant Vaccine, which addendum shall reflect factors such as the Variant Vaccine cost, timing and supply amount.